References
- Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398–1405.
- Kreutzman A, Juvonen V, Kairistro V, et al. Monoclonal/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010;116: 772–782.
- Kreutzman A, Ladell K, Koechel C, et al. Expansion of highly differentiated CD8 + T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 2011;25:1587–1597.
- Powers JJ, Dubovsky JA, Epling-Burnette PK, et al. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma 2011;52:668–679.
- Kim DH, Kamel-Reid S, Chang H, et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009;94:135–139.
- Li W, HongLi Z, XueDong S, et al. Comparison of Wilms’ tumor antigen 1-specific T lymphocyte generation soon after nonmyeloablative allergenic stem-cell transplantation in acute and chronic leukemia patients. Int J Hematol 2010;91:652–660.
- Tsuboi A, Oka Y, Kyo T, et al. Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease. Leukemia 2012;26:1410–1413.
- Hashii Y, Sato-Miyashita E, Matsusmura R, et al. WT1 peptide vaccination following allogeneic stem cell transplantation in pediatric leukemic patients with high risk for relapse;successful maintenance of durable remission. Leukemia 2012;26:530–532.
- Rodriguez-Caballero A, Garcia-Montero AC, Barcena P, et al. Expanded cells in monoclonal TCR-αβ+/CD4+/NKa+/CD8−/+ dimT-LGL lymphocytosis recognize hCMV antigens. Blood 2008;112:4609–4616.
- Fei F, Yu Y, Schmitt A, et al. Dasatinib exerts an immunosuppressive effect on CD8 + T cells specific for viral and leukemia antigens. Exp Hematol 2008;36:1297–1308.
- Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008;111:1366–1377.
- Bantscheff M, Eberhard D, Abraham Y, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007;25:1035–1044.